These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 1719248)

  • 1. An improved vasoactive drug combination for a pharmacological erection program.
    Bennett AH; Carpenter AJ; Barada JH
    J Urol; 1991 Dec; 146(6):1564-5. PubMed ID: 1719248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Intracavernous injection of vasoactive drugs for treating erectile impotence].
    Yasumoto R; Asakawa M; Kawashima H; Yoshimura R; Maekawa T; Kashiwara N; Tanaka H; Nishio S
    Hinyokika Kiyo; 1988 Feb; 34(2):301-4. PubMed ID: 2454019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intracavernous injection of prostaglandin E1 in combination with papaverine: enhanced effectiveness in comparison with papaverine plus phentolamine and prostaglandin E1 alone.
    Floth A; Schramek P
    J Urol; 1991 Jan; 145(1):56-9. PubMed ID: 1984099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of a mixture of papaverine, phentolamine and prostaglandin E1 with other intracavernous injections.
    Meinhardt W; Lycklama à Nijeholt AA; Kropman RF; Vermeij P; Zwartendijk J
    Eur Urol; 1994; 26(4):319-21. PubMed ID: 7713130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [3 years' experience with intracavernous auto-injection therapy].
    Weiske WH
    Urologe A; 1989 Sep; 28(5):253-6. PubMed ID: 2815435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostaglandin E1 versus phentolamine/papaverine for the treatment of erectile impotence: a double-blind comparison.
    Lee LM; Stevenson RW; Szasz G
    J Urol; 1989 Mar; 141(3):549-50. PubMed ID: 2918589
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Experience with triple-drug therapy in a pharmacological erection program.
    Govier FE; McClure RD; Weissman RM; Gibbons RP; Pritchett TR; Kramer-Levien D
    J Urol; 1993 Dec; 150(6):1822-4. PubMed ID: 8230514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative study of papaverine plus phentolamine versus prostaglandin E1 in erectile dysfunction.
    Bechara A; Casabé A; Chéliz G; Romano S; Rey H; Fredotovich N
    J Urol; 1997 Jun; 157(6):2132-4. PubMed ID: 9146599
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical evaluation of intracavernous self-injection of vasoactive drugs for impotence: a long-term follow-up observation].
    Hayashi S; Iwai Y; Yasumoto R; Matsuda J; Kawano M; Omachi T; Kono T; Yamamoto S; Sakakura T; Minami H
    Hinyokika Kiyo; 1994 Jan; 40(1):37-41. PubMed ID: 7509119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Papaverine-phentolamine and prostaglandin E1 versus papaverine-phentolamine alone for intracorporeal injection therapy: a clinical double-blind study.
    Shenfeld O; Hanani J; Shalhav A; Vardi Y; Goldwasser B
    J Urol; 1995 Sep; 154(3):1017-9. PubMed ID: 7637045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prostaglandin E1 in erectile dysfunction].
    Porst H
    Urologe A; 1989 Mar; 28(2):94-8. PubMed ID: 2655258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostaglandin E1 with phentolamine for the treatment of erectile dysfunction.
    Meinhardt W; de la Fuente RB; Lycklama à Nijeholt AA; Vermeij P; Zwartendijk J
    Int J Impot Res; 1996 Mar; 8(1):5-7. PubMed ID: 8735187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drop-out reasons and complications in self-injection therapy with a triple vasoactive drug mixture in sexual erectile dysfunction.
    Casabé A; Bechara A; Cheliz G; Romano S; Rey H; Fredotovich N
    Int J Impot Res; 1998 Mar; 10(1):5-9. PubMed ID: 9542684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical reliability of multi-drug intracavernous vasoactive pharmacotherapy for diabetic impotence.
    Montorsi F; Guazzoni G; Bergamaschi F; Zucconi M; Rigatti P; Pizzini G; Miani A; Pozza G
    Acta Diabetol; 1994 Apr; 31(1):1-5. PubMed ID: 8043890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacologic erection program for the treatment of male impotence.
    Trapp JD
    South Med J; 1987 Apr; 80(4):426-7. PubMed ID: 2436316
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intracavernous pharmacotherapy for impotence: selection of appropriate agent and dose.
    von Heyden B; Donatucci CF; Kaula N; Lue TF
    J Urol; 1993 May; 149(5 Pt 2):1288-90. PubMed ID: 8479018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Current role of intracavernous therapy in the treatment of erectile dysfunction].
    Asuar Aydillo S
    Arch Esp Urol; 2002 Jun; 55(5):475-82. PubMed ID: 12174413
    [No Abstract]   [Full Text] [Related]  

  • 18. Objective double-blind evaluation of erectile function with intracorporeal papaverine in combination with phentolamine and/or prostaglandin E1.
    Allen RP; Engel RM; Smolev JK; Brendler CB
    J Urol; 1992 Oct; 148(4):1181-3. PubMed ID: 1404632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Calcitonin-gene-related peptide: a possible role in human penile erection and its therapeutic application in impotent patients.
    Stief CG; Wetterauer U; Schaebsdau FH; Jonas U
    J Urol; 1991 Oct; 146(4):1010-4. PubMed ID: 1895414
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prostaglandin E1 versus mixture of prostaglandin E1, papaverine and phentolamine in nonresponders to high papaverine plus phentolamine doses.
    Bechara A; Casabé A; Chéliz G; Romano S; Fredotovich N
    J Urol; 1996 Mar; 155(3):913-4. PubMed ID: 8583605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.